A Phase 3, Randomized, open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 expression ≥1%

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513682-40-01

Acronym

CA2241093

Enrollment

288

Registered

2025-06-11

Start date

2025-07-04

Completion date

Unknown

Last updated

2025-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer

Brief summary

Comparison of overall survival in Arm A and Arm B participants.

Detailed description

Comparison of PFS in Arm A and Arm B participant, as well as evaluation of DoR and ORR in Arm A and B participants., Safety of study drugs administered will be evaluated, along with TTD

Interventions

DRUGRelatlimab + Nivolumab Fixed Dose Combination (FDC)

DRUGCISPLATIN

DRUGPEMBROLIZUMAB

DRUGCARBOPLATIN

DRUGPEMETREXED DISODIUM

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Comparison of overall survival in Arm A and Arm B participants.	—

Secondary

Measure	Time frame
Comparison of PFS in Arm A and Arm B participant, as well as evaluation of DoR and ORR in Arm A and B participants., Safety of study drugs administered will be evaluated, along with TTD	—

Countries

Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Poland, Portugal, Romania, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026